X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ATA-200 is a single-injection gene therapy, which is being evaluated for the treatment of the γ-sarcoglycan related limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5).
Lead Product(s): ATA-200
Therapeutic Area: Genetic Disease Product Name: ATA-200
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The financing will be used to support company's clinical trials and manufacturing development programs, including ATA-200 gene therapy targeting γ-sarcoglycan (SGCG) related limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5).
Lead Product(s): ATA-200
Therapeutic Area: Genetic Disease Product Name: ATA-200
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $8.6 million Upfront Cash: Undisclosed
Deal Type: Financing September 19, 2023
Details:
ATA-200, is the gene therapy that delivers a normal copy of the gene for production of γ-sarcoglycan, which is investigated for limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5).
Lead Product(s): ATA-200
Therapeutic Area: Genetic Disease Product Name: ATA-200
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
ATA-100 (GNT0006), a single-administration gene therapy candidate for LGMD2I/R9, delivers a normal copy of the gene for production of FKRP proteins, which is investigated for the treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9).
Lead Product(s): GNT0006
Therapeutic Area: Genetic Disease Product Name: ATA-100
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
First approval of ATA-100, was received from UK MHRA its gene therapy for the treatment of the fukutin-related protein limb-girdle muscular dystrophy Type 2I/R9.
Lead Product(s): ATA-100
Therapeutic Area: Genetic Disease Product Name: ATA-100
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
